Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial

Abstract: Mitochondrial dysfunction plays a major role in the pathogenesis of Parkinson disease (PD). Creatine (Cr) is an ergogenic compound that exerts neuroprotective effects in animal models of PD. We conducted a 2-year placebo-controlled randomized clinical trial on the effect of Cr in 60 patients with PD. Cr improved patient mood and led to a smaller dose increase of dopaminergic therapy but had no effect on overall Unified Parkinson’s Disease Rating Scale scores or dopamine transporter SPECT.

Link to article: https://www.neurology.org/doi/10.1212/01.wnl.0000238518.34389.12?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

PubMed: https://pubmed.ncbi.nlm.nih.gov/17030762/

Authors: A Bender, W Koch, M Elstner, Y Schombacher, J Bender, M Moeschl, F Gekeler, B Müller-Myhsok, T Gasser, K Tatsch, T Klopstock

Key Terms:  General Creatine, Clinical Study, Supplements, Non-CCDS Disease, Adult Patient